Haisco Pharmaceutical Group (002653.SZ)

Executive Summary

Haisco Pharmaceutical Group is a Chinese biopharmaceutical company with a market capitalization of approximately $7.9 billion, focusing on innovative drugs in oncology, cardiovascular, respiratory, and other therapeutic areas. The company's pipeline is anchored by several key assets: HSK39297, a Phase 3 candidate for IgA Nephropathy (IgAN) which is currently recruiting with a completion date in 2028; HSK47388, a Phase 2 agent for plaque psoriasis expected to complete enrollment in early 2027; and Crisugabalin, already approved for Parkinson's disease-related nociceptive pain with an active post-market study. Additionally, HSK3486, an anesthetic/sedative, is in Phase 1 development. Haisco's strategy emphasizes both novel and generic drugs, leveraging its R&D capabilities to address unmet medical needs in China and potentially globally. The company's public listing on the Shenzhen Stock Exchange provides access to capital for its pipeline advancement.

Upcoming Catalysts (preview)

• Q4 2026HSK39297 Phase 3 interim data or enrollment update in IgA Nephropathy60% success
• H1 2027HSK47388 Phase 2 top-line results in plaque psoriasis40% success
• Q3 2026Crisugabalin post-market study results in Parkinson's pain90% success